The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Prevention of preeclampsia with aspirin
Abstract
Preeclampsia is defined as hypertension arising after 20 weeks of gestational age with proteinuria or other signs of end-organ damage and is a significant cause of maternal and perinatal morbidity and mortality, particularly when of early onset. Although a significant amount of research has been dedicated in identifying preventive measures for preeclampsia, the incidence of the condition has been relatively unchanged in the last decades. This could be attributed to the fact that the underlying pathophysiology of preeclampsia is not entirely understood. There is increasing evidence suggesting that suboptimal trophoblastic invasion leads to an imbalance of angiogenic and anti-angiogenic proteins, ultimately causing widespread inflammation and endothelial damage, increased platelet aggregation and thrombotic events with placental infarcts. Aspirin at doses below 300 mg selectively and irreversibly inactivates the cyclooxygenase-1 enzyme, suppressing the production of prostaglandins and thromboxane and inhibiting inflammation and platelet aggregation. Such an effect has led to the hypothesis that aspirin could be useful for preventing preeclampsia. The first possible link between the use of aspirin and the prevention of preeclampsia was suggested by a case report published in 1978, followed by the first randomized controlled trial published in 1985. Since then, numerous randomized trials have been published, demonstrating the safety of the use of aspirin in pregnancy and the inconsistent effects of aspirin on the rates of preeclampsia. These inconsistencies, however, can be largely explained by a high degree of heterogeneity regarding the selection of trial participants, baseline risk of the included women, dose of aspirin, gestational age of prophylaxis initiation and preeclampsia definition. An individual patient data meta-analysis has demonstrated a modest 10% reduction in preeclampsia rates with the use of aspirin, but later meta-analyses of aggregate data have shown a dose-response effect of aspirin on preeclampsia rates, which is maximized when the medication is initiated before 16 weeks of gestational age. Recently, the Aspirin for Evidence-based Preeclampsia Prevention (ASPRE) trial has demonstrated that aspirin at a daily dose of 150 mg, initiated before 16 weeks of gestational age, and given at night to a high-risk population, identified by a combined first trimester screening test, reduces the incidence of preterm preeclampsia by 62%. A secondary analysis of the ASPRE trial data also demonstrated a reduction in the length of stay in the neonatal intensive care unit by 68%, compared with placebo, mainly due to a reduction in births before 32 weeks of gestational age with preeclampsia. The beneficial effect of aspirin has been shown to be similar in subgroups according to different maternal characteristics, except for the presence of chronic hypertension, where no beneficial effect is evident. In addition, the effect size of aspirin has been shown to be more pronounced in women with good compliance to treatment. In general, randomized trials are underpowered to investigate the treatment effect of aspirin on the rates of other placental-associated adverse outcomes such as fetal growth restriction and stillbirth. This article summarizes the evidence around aspirin for the prevention of preeclampsia and its complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Epidemiology and causes of preterm birth
Goldenberg, R. L., Culhane, J. F., Iams, J. D., & Romero, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60074-4 · Cited by 7,801 · cited 1×
“A subset of pregnant women with spontaneous preterm birth has placental lesions associated with uteroplacental ischemia and abnormal uterine artery Doppler, findings that are frequently observed in women with preeclampsia, and therefore, it has been suggested that placental insufficiency may play a role in the spontan…”
BackgroundHansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The Global Impact of Pre-eclampsia and Eclampsia
Duley, L. (2009) · Seminars in Perinatology · doi:10.1053/j.semperi.2009.02.010 · Cited by 2,866
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Self-citationMosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Long-Term Medical and Social Consequences of Preterm Birth
Moster, D., Lie, R. T., & Markestad, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706475 · Cited by 1,402
Pre-eclampsia: pathophysiology and clinical implications
Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019) · BMJ · doi:10.1136/bmj.l2381 · Cited by 1,250
Poon, L. C., Shennan, A., Hyett, J. A., Kapur, A., Hadar, E., Divakar, H., McAuliffe, F., da Silva Costa, F., von Dadelszen, P., McIntyre, H. D., et al. (2019) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12802 · Cited by 1,238
Self-citationThe mechanism of action of aspirin
Vane, J. R., & Botting, R. M. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00379-7 · Cited by 1,225
Cited by
Magee, L. A., Brown, M. A., Hall, D. R., Gupte, S., Hennessy, A., Karumanchi, S. A., Kenny, L. C., McCarthy, F., Myers, J., Poon, L. C., et al. (2022) · Pregnancy Hypertension · doi:10.1016/j.preghy.2021.09.008 · Cited by 1,134
Self-citationChang, K.-J., Seow, K.-M., & Chen, K.-H. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20042994 · Cited by 266
The exciting potential for ChatGPT in obstetrics and gynecology
Grünebaum, A., Chervenak, J., Pollet, S. L., Katz, A., & Chervenak, F. A. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.03.009 · Cited by 234
Lee, J. C., Badell, M. L., & Kawwass, J. F. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00869-z · Cited by 41
Malone, S. L., Haj Yahya, R., & Kane, S. C. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s283239 · Cited by 32
Metadata
- Authors
- Rolnik, D. L., Nicolaides, K. H., & Poon, L. C.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 226
- Issue
- 2
- Pages
- S1108-S1119
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W3081112584
- Cited by
- 390
- References
- 85
- FWCI
- 20.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of preeclampsia with aspirin. https://app.cochat.ai/papers/10.1016/j.ajog.2020.08.045
- The paper
- Rolnik, D. L., Nicolaides, K. H., & Poon, L. C. (2022). Prevention of preeclampsia with aspirin. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2020.08.045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.